Dravet Syndrome (DS)

Neurology·MeSH: Epilepsies, Myoclonic

Prevalence

5.0 / 100K

5 drugs in development·4 companies·5 clinical trials

Drug Pipeline by Phase

Phase 3(4)

Drug	Company
EPX-100	Harmony Biosciences Holdings, Inc. (HRMY)
soticlestat	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
soticlestat	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
soticlestat	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Preclinical(1)

Drug	Company
nobrxiol	Virpax Pharmaceuticals, Inc. (VRPX)

BioSniper tracks 5 drugs in development for Dravet Syndrome (DS) across 4 companies.

There are 5 clinical trials targeting Dravet Syndrome (DS) tracked by BioSniper.

The estimated prevalence of Dravet Syndrome (DS) is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.